Taiwan Advanced Nanotech

Taiwan Advanced Nanotech Current Liabilities

The Current Liabilities of Taiwan Advanced Nanotech (6797.TWO) as of Nov 11, 2026 is 7.06 M TWD. In the previous year, Current Liabilities was 171.16 M TWD — a change of -95.88% (lower).

Current Liabilities

7.06 MTWD

YoY

-95.88%

Last updated:

Current Liabilities of Taiwan Advanced Nanotech is 2025 7.06 M TWD. Current Liabilities of Taiwan Advanced Nanotech was 2024 171.16 M TWD. It decreases by -95.88% lower compared to the previous year.

The Taiwan Advanced Nanotech Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
35.15 M TWD
Jan 1, 2019
80.82 M TWD
Jan 1, 2020
616.24 M TWD
Jan 1, 2021
505.40 M TWD
Jan 1, 2022
556.38 M TWD
Jan 1, 2023
431.68 M TWD
Jan 1, 2024
171.16 M TWD
Jan 1, 2025
7.06 M TWD
The Taiwan Advanced Nanotech Current Liabilities history
YEARCurrent LiabilitiesYoY
7.06 MTWD-95.88%
171.16 MTWD-60.35%
431.68 MTWD-22.41%
556.38 MTWD+10.09%
505.40 MTWD-17.99%
616.24 MTWD+662.49%
80.82 MTWD+129.93%
35.15 MTWD+43.75%
24.45 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Taiwan Advanced Nanotech Stock analysis

What does Taiwan Advanced Nanotech do? Taiwan Advanced Nanotech, Inc. generates revenue through the sale of nucleic acid purification products, including SLA series, Maelstrom series, and LH series instruments designed for DNA/RNA extraction. The company also sells specialized reagents such as virus nucleic acid extraction reagent 665 series, blood nucleic acid extraction reagent 611/61E series, and tissue nucleic acid extraction reagent 6T2/6K2 series. These products are marketed to customers in Taiwan, South Korea, and China, with sales primarily focused on laboratory and medical applications requiring nucleic acid processing. The company's product portfolio targets research institutions, diagnostic laboratories, and healthcare facilities seeking efficient nucleic acid extraction solutions. By offering a range of instruments and reagents tailored to specific extraction needs, Taiwan Advanced Nanotech addresses key segments in the biotechnology and medical diagnostics markets. Sales are distributed across Taiwan, South Korea, and China, reflecting the company's regional market focus. Revenue streams are derived from direct sales of instruments and reagents to end-users in the biotech and healthcare sectors. The SLA, Maelstrom, and LH series instruments serve as core revenue drivers, complemented by recurring reagent sales for ongoing laboratory operations. This dual-product approach ensures steady income from both capital equipment and consumable supplies. Taiwan Advanced Nanotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Taiwan Advanced Nanotech stock

Current Liabilities of Taiwan Advanced Nanotech is 7.06 M TWD in 2025.

Current Liabilities of Taiwan Advanced Nanotech changed from 171.16 M TWD to 7.06 M TWD, representing a -95.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Taiwan Advanced Nanotech since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Taiwan Advanced Nanotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Taiwan Advanced Nanotech

All Key Metrics — Taiwan Advanced Nanotech